Phase III trial of telatinib in combination with a standard chemotherapy regimen for advanced gastric cancer
Phase of Trial: Phase III
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Antineoplastics; Telatinib
- Indications Gastric cancer
- Focus Registrational; Therapeutic Use
- 02 Jun 2011 The FDA has approved the design of this trial under a Special Protocol Assessment.
- 28 Feb 2011 ACT Biotech has filed a Special Protocol Assessment (SPA) with the US FDA for this trial, according to an ACT Biotech media release.
- 13 Oct 2010 ACT Biotech is on track to file for marketing approval in the USA and Europe in 2014, according to a ACT Biotech media release.